The investment will be used to advance new treatments for limb-girdle and facioscapulohumeral muscular dystrophy, the company said. The series B funding round was led by Cambrian BioPharma. Vita Therapeutics has raised $66 million to date.
“The support from this strategic group of quality investors further validates Vita’s cell therapy platform and our mission to bring transformative therapies that target the root cause of disease to patients with muscle disorders and cancers,” Vita Therapeutics CEO Douglas Falk said in the Oct. 12 company news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.